British politicians from across party lines delivered a blunt message this week. The United Kingdom has grown dangerously dependent on Palantir Technologies. That dependence now poses risks too large to ignore.
A report from Parliament’s Science, Innovation and Technology Committee lays out the case in stark terms. The 11 MPs describe the country’s expanding contracts with the American data analytics firm as “an unacceptable point of weakness.” They fear vendor lock-in will drive up costs, degrade service quality and hand Palantir excessive leverage in future talks. WIRED first detailed the findings hours after publication on June 2, 2026.
Dame Chi Onwurah chairs the committee. She told WIRED the pattern is familiar. “We know that with vendor lock-in, over time, we’ll get more expensive and worse services. It’s a trap that has to be avoided.” Her worry runs deeper. A supplier so embedded could one day threaten to pull service. “That could bring public services and our economy to a halt. That’s a huge risk.”
The concerns stretch beyond money and technical architecture. The report highlights a clear mismatch with UK values. Palantir co-founder Peter Thiel once likened British attachment to the NHS to Stockholm syndrome. A 22-point manifesto drawn from a recent book by chief executive Alex Karp calls for unwavering loyalty to American interests above all else. Onwurah sees trouble. “We have a key vendor saying they will exercise technology in accordance with their political mission. If what the UK is trying to do in our NHS or our defense does not align with Palantir’s political objectives, we clearly can’t depend upon them as a supplier.”
These tensions did not appear overnight. The partnership began in 2020. Britain faced a raging pandemic. Officials turned to Palantir to map Covid-19 spread and direct scarce medical supplies. The initial deal was small. Success bred expansion. Palantir and its partners have since secured contracts totaling some $750 million across the National Health Service and Ministry of Defence. The company promotes its tools as drivers of innovation and rapid problem solving inside government.
Yet the committee singles out Palantir above other foreign suppliers. It notes parallel reliance on Microsoft, Amazon Web Services and Japan’s Fujitsu, the latter scarred by its role in the Post Office Horizon scandal. Still the MPs write that Palantir concerns us most. Recent scrutiny has intensified. The firm’s contracts with US Immigration and Customs Enforcement, its support for American and Israeli military operations, and the ideological tone of its leadership have all fueled debate.
Donald Campbell directs advocacy at Foxglove, a nonprofit that has long pushed to sever NHS ties with the company. He pulls no punches. “They’re not a company that should be anywhere near British public services. Do you want to be giving a company of this kind—with these openly expressed opinions and ideologies—a central role in the UK state that it may get harder and harder to remove them from?”
Palantir offered a different view when its European chief Louis Mosley appeared before the committee in July 2025. He distanced the firm from Thiel’s NHS remark. The company’s goal, he said, is to “support democratically elected governments in delivering the mandate that they have been elected to deliver. We represent a diversity of political views and do not take political positions as a company.” Palantir did not respond to requests for comment on the new report.
Recent weeks have brought fresh fuel to the fire. In May 2026 the Financial Times revealed NHS England granted Palantir staff and other contractors unlimited access to identifiable patient data before pseudonymisation. Internal briefing notes acknowledged the risk of lost public confidence. MPs reacted sharply. Rachael Maskell, a former NHS worker, called the move dangerous. “As Palantir get their claws deeper into our NHS data we can see how it is opening it up to greater private interest. This is a dangerous development and I ask the government to get a grip on this project before it is too late.” The Guardian covered the backlash on May 11.
The centerpiece of controversy remains the £330 million Federated Data Platform contract signed in 2023. It aims to unify disparate health datasets across England. NHS England insists Palantir acts only as a processor under strict instruction, cannot commercialize the data and holds no intellectual property rights in it. Yet campaigners question whether those safeguards hold in practice. A March 2026 briefing from Medact, backed by doctors, patients and human rights groups, catalogued risks ranging from data security to potential mission creep into policing or immigration enforcement. It urged NHS trusts to refuse participation. Medact published the document on March 12.
Critics also challenge the platform’s actual performance. Some NHS insiders describe the software as overpriced and less effective than existing tools for querying, analytics and visualization. One clinician told technology analyst Rory Cellan-Jones the system functions mainly as a costly data warehouse. Questions swirl too around pilot results at trusts like Chelsea and Westminster. Data used to promote early success has come under fire in the British Medical Journal.
Defenders counter that political noise threatens a necessary modernization drive. The NHS strains under outdated systems. Proponents argue that rejecting capable technology on ideological grounds only delays improvements in patient care and operational efficiency. A Financial Times opinion piece last year warned against letting grievances derail Britain’s ambition to become a truly digital state.
But trust remains the core issue. Eerke Boiten, professor of cybersecurity at De Montfort University, captures the bind. “These companies are such a size, we can’t really inspect what they’re doing. If data needs to be operated on, in 99 percent of cases the provider will need to be able to see the data. That means you have to trust them.”
The committee offers a concrete recommendation. NHS England should trigger an early termination clause available next February. Ministers have signaled openness to review. In April 2026 junior health minister Zubir Ahmed told Parliament the government would reconsider if better alternatives emerge. Petitions carrying hundreds of thousands of signatures demand full exit. Over 47,000 patients have written directly to local trusts.
Broader patterns worry observers. An investigation by The Nerve, published in February 2026, tallied at least 34 UK public sector contracts with Palantir worth more than £900 million when including a major Ministry of Defence extension signed late last year. The total spans health, defense, police, intelligence and even financial regulators. Two senior MoD systems engineers spoke anonymously to the outlet, labeling the data exposure a national security threat. Switzerland, by contrast, reviewed similar evidence and walked away.
And the debate continues. Campaign coalitions including the Good Law Project, Privacy International, Amnesty International and trade unions have mobilized against the arrangement. They argue sensitive citizen data should not rest with a firm whose other clients include entities accused of human rights controversies. Supporters of the partnership insist proper contracts, oversight and data protection law provide adequate guardrails. NHS England’s own contract explainer stresses that Palantir cannot use the data to train models or pursue independent commercial aims.
So the central question lingers. Can a democratic government outsource core analytical capabilities over sensitive population data to a foreign commercial actor whose leaders openly prioritize another nation’s strategic interests? The parliamentary committee believes the current trajectory fails that test. Its members want action before dependence becomes irreversible. Whether ministers will pull the break clause or press ahead with digital transformation at any cost will shape Britain’s approach to technology sovereignty for years ahead.
Fresh reporting since the committee’s release shows the story is far from settled. Discussions on X reflect divided opinion, with some users praising Palantir’s technical edge while others echo the MPs’ sovereignty warnings. No easy resolution appears on the horizon. The stakes, however, could hardly be higher. Patient records. Defense planning. Public service delivery. All now flow through systems built and maintained by one American company. The politicians have issued their warning. The government must now decide how seriously to take it.
WebProNews is an iEntry Publication